Cargando…

Perhexiline Therapy in Patients with Type 2 Diabetes: Incremental Insulin Resistance despite Potentiation of Nitric Oxide Signaling

Perhexiline (Px) inhibits carnitine palmitoyltransferase 1 (CPT1), which controls uptake of long chain fatty acids into mitochondria. However, occasional cases of hypoglycaemia have been reported in Px-treated patients, raising the possibility that Px may also increase sensitivity to insulin. Furthe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chong, Cher-Rin, Liu, Saifei, Imam, Hasan, Heresztyn, Tamila, Sallustio, Benedetta C., Chirkov, Yuliy Y., Horowitz, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598312/
https://www.ncbi.nlm.nih.gov/pubmed/36289640
http://dx.doi.org/10.3390/biomedicines10102381
_version_ 1784816302291943424
author Chong, Cher-Rin
Liu, Saifei
Imam, Hasan
Heresztyn, Tamila
Sallustio, Benedetta C.
Chirkov, Yuliy Y.
Horowitz, John D.
author_facet Chong, Cher-Rin
Liu, Saifei
Imam, Hasan
Heresztyn, Tamila
Sallustio, Benedetta C.
Chirkov, Yuliy Y.
Horowitz, John D.
author_sort Chong, Cher-Rin
collection PubMed
description Perhexiline (Px) inhibits carnitine palmitoyltransferase 1 (CPT1), which controls uptake of long chain fatty acids into mitochondria. However, occasional cases of hypoglycaemia have been reported in Px-treated patients, raising the possibility that Px may also increase sensitivity to insulin. Furthermore, Px increases anti-aggregatory responses to nitric oxide (NO), an effect which may theoretically parallel insulin sensitization. We therefore sought to examine these relationships in patients with stable Type 2 diabetes (T2D) and cardiovascular disease (n = 30). Px was initiated, and dosage was titrated, to reach the therapeutic range and thus prevent toxicity. Investigations were performed before and after 2 weeks, to examine changes in insulin sensitivity and, utilizing aggregometry in whole blood, platelet responsiveness to the anti-aggregatory effects of the NO donor sodium nitroprusside (SNP). Other parameters that affect may affect NO signalling were also evaluated. Px substantially potentiated inhibition of platelet aggregation by SNP (from 16.7 ± 3.0 to 27.3 ± 3.7%; p = 0.005). Px did not change fasting blood glucose concentrations but reduced insulin sensitivity (HOMA-IR score increased from median of 4.47 to 6.08; p = 0.028), and increased fasting plasma insulin concentrations (median 16.5 to 19.0 mU/L; p = 0.014). Increases in SNP responses tended (r = −0.30; p = 0.11) to be reciprocally related to increases in HOMA-IR, and increases in HOMA-IR were greater (p = 0.002) in patients without NO-sensitizing effects. No patient developed symptomatic hypoglycaemia, nor was there any other short-term toxicity of Px. Thus, in patients with stable T2D and cardiovascular disease, Px increases anti-aggregatory responsiveness to NO, but is not an insulin sensitizer, and does not induce hypoglycaemia. Absence of NO-sensitizing effect occurs in approximately 30% of Px-treated patients with T2D, and is associated with induction of insulin resistance in these patients.
format Online
Article
Text
id pubmed-9598312
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95983122022-10-27 Perhexiline Therapy in Patients with Type 2 Diabetes: Incremental Insulin Resistance despite Potentiation of Nitric Oxide Signaling Chong, Cher-Rin Liu, Saifei Imam, Hasan Heresztyn, Tamila Sallustio, Benedetta C. Chirkov, Yuliy Y. Horowitz, John D. Biomedicines Article Perhexiline (Px) inhibits carnitine palmitoyltransferase 1 (CPT1), which controls uptake of long chain fatty acids into mitochondria. However, occasional cases of hypoglycaemia have been reported in Px-treated patients, raising the possibility that Px may also increase sensitivity to insulin. Furthermore, Px increases anti-aggregatory responses to nitric oxide (NO), an effect which may theoretically parallel insulin sensitization. We therefore sought to examine these relationships in patients with stable Type 2 diabetes (T2D) and cardiovascular disease (n = 30). Px was initiated, and dosage was titrated, to reach the therapeutic range and thus prevent toxicity. Investigations were performed before and after 2 weeks, to examine changes in insulin sensitivity and, utilizing aggregometry in whole blood, platelet responsiveness to the anti-aggregatory effects of the NO donor sodium nitroprusside (SNP). Other parameters that affect may affect NO signalling were also evaluated. Px substantially potentiated inhibition of platelet aggregation by SNP (from 16.7 ± 3.0 to 27.3 ± 3.7%; p = 0.005). Px did not change fasting blood glucose concentrations but reduced insulin sensitivity (HOMA-IR score increased from median of 4.47 to 6.08; p = 0.028), and increased fasting plasma insulin concentrations (median 16.5 to 19.0 mU/L; p = 0.014). Increases in SNP responses tended (r = −0.30; p = 0.11) to be reciprocally related to increases in HOMA-IR, and increases in HOMA-IR were greater (p = 0.002) in patients without NO-sensitizing effects. No patient developed symptomatic hypoglycaemia, nor was there any other short-term toxicity of Px. Thus, in patients with stable T2D and cardiovascular disease, Px increases anti-aggregatory responsiveness to NO, but is not an insulin sensitizer, and does not induce hypoglycaemia. Absence of NO-sensitizing effect occurs in approximately 30% of Px-treated patients with T2D, and is associated with induction of insulin resistance in these patients. MDPI 2022-09-23 /pmc/articles/PMC9598312/ /pubmed/36289640 http://dx.doi.org/10.3390/biomedicines10102381 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chong, Cher-Rin
Liu, Saifei
Imam, Hasan
Heresztyn, Tamila
Sallustio, Benedetta C.
Chirkov, Yuliy Y.
Horowitz, John D.
Perhexiline Therapy in Patients with Type 2 Diabetes: Incremental Insulin Resistance despite Potentiation of Nitric Oxide Signaling
title Perhexiline Therapy in Patients with Type 2 Diabetes: Incremental Insulin Resistance despite Potentiation of Nitric Oxide Signaling
title_full Perhexiline Therapy in Patients with Type 2 Diabetes: Incremental Insulin Resistance despite Potentiation of Nitric Oxide Signaling
title_fullStr Perhexiline Therapy in Patients with Type 2 Diabetes: Incremental Insulin Resistance despite Potentiation of Nitric Oxide Signaling
title_full_unstemmed Perhexiline Therapy in Patients with Type 2 Diabetes: Incremental Insulin Resistance despite Potentiation of Nitric Oxide Signaling
title_short Perhexiline Therapy in Patients with Type 2 Diabetes: Incremental Insulin Resistance despite Potentiation of Nitric Oxide Signaling
title_sort perhexiline therapy in patients with type 2 diabetes: incremental insulin resistance despite potentiation of nitric oxide signaling
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598312/
https://www.ncbi.nlm.nih.gov/pubmed/36289640
http://dx.doi.org/10.3390/biomedicines10102381
work_keys_str_mv AT chongcherrin perhexilinetherapyinpatientswithtype2diabetesincrementalinsulinresistancedespitepotentiationofnitricoxidesignaling
AT liusaifei perhexilinetherapyinpatientswithtype2diabetesincrementalinsulinresistancedespitepotentiationofnitricoxidesignaling
AT imamhasan perhexilinetherapyinpatientswithtype2diabetesincrementalinsulinresistancedespitepotentiationofnitricoxidesignaling
AT heresztyntamila perhexilinetherapyinpatientswithtype2diabetesincrementalinsulinresistancedespitepotentiationofnitricoxidesignaling
AT sallustiobenedettac perhexilinetherapyinpatientswithtype2diabetesincrementalinsulinresistancedespitepotentiationofnitricoxidesignaling
AT chirkovyuliyy perhexilinetherapyinpatientswithtype2diabetesincrementalinsulinresistancedespitepotentiationofnitricoxidesignaling
AT horowitzjohnd perhexilinetherapyinpatientswithtype2diabetesincrementalinsulinresistancedespitepotentiationofnitricoxidesignaling